Antonio Iavarone
University of Miami, FL·Medicine & Clinical Research
Glioblastoma is one of the deadliest human cancers, and a major reason treatments fail is that no two tumors, and no two cells within a tumor, are quite alike. This genomic and phenotypic complexity means a drug that works on part of a tumor may leave other parts untouched.
- Fields
Medicine & Clinical Research
Genetics
Biology
- Topics
glioblastoma
malignant glioma
brain tumors
- Grants
- 1 known grant, through Aug 2028
What they work on
- Identify homogeneous subgroups of brain tumors that share activation of the same biological pathways, using integrated computational analysis of patient tumor data to improve molecular stratification of glioblastoma.
- Develop and apply high-throughput single-cell transcriptomic and proteomic methods to malignant glioma tissue, to measure how individual tumor cells differ and to inform more accurate tumor classification.
- Extract the genes and proteins that determine the phenotypic state of individual glioma cells, pinpointing master regulators and driver modules through computational analysis of single-cell data.
- Test predicted synthetic lethal relationships and pathway dependencies, including oncogene-dependent and oncogene-independent vulnerabilities, in sequence-annotated patient-derived glioma models in vitro and in vivo.
More about the research
The research program here asks how to sort patients into biologically meaningful groups, identify the specific pathways each tumor depends on, and use that information to predict which drugs will work. The long-term goal is to model, predict and target both sensitivity and resistance in glioblastoma.
Why it matters
Glioblastoma remains almost uniformly lethal, and treatment failure is attributed largely to the genetic and cellular diversity of these tumors. By defining subgroups that share active pathways and pinpointing the pathways individual tumor cells cannot survive without, this work could yield therapeutic targets and predictions of which patients will respond to which drug, supporting more personalized treatment for brain tumor patients.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Gordon Mills
Oregon Health & Science University, OR·Medicine & Clinical Research
Develop computational algorithms that predict which cancer point mutations and fusion genes are neomorphic drivers, changes that give proteins new functions.
Atique Ahmed
Northwestern University, IL·Medicine & Clinical Research
Run a Phase 1/1b trial of mycophenolate mofetil, an IMPDH2-blocking transplant drug, combined with temozolomide and radiation in newly diagnosed glioblastoma, to set the maximum tolerated dose and assess safety.
Dolores Hambardzumyan
University of Pennsylvania, PA·Microbiology & Immunology
Map how glioblastoma subtype and location shape monocyte and neutrophil infiltration, using single-cell RNA sequencing, spatial multiomics and multiplex flow cytometry in mice carrying human tumor-driving mutations.
The school
University of Miami: 30 labs on PI Pages, $559M a year on research, 297 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.